Supporting Development Of mRNA Therapeutics By Enabling Commercial-Scale mRNA Purification

Messenger RNA (mRNA) therapeutics have rapidly moved beyond vaccines and are now exploring an ever-growing number of clinical indications. To keep pace with this expansion, the life sciences industry needs scalable and efficient purification solutions for commercial production.

Explore the advantages of using affinity capture as a critical step in isolating and purifying high-quality mRNA. Learn about a novel affinity resin, POROS™ Oligo dT(25), that simplifies the purification process by utilizing a simple, reliable AT base-pairing mechanism for binding. This approach is designed to help you maximize efficiency and streamline your process—from early development at the bench through large-scale manufacturing.

Learn how this new technology can simplify your workflow and ensure your process is ready for the rapid growth of the mRNA therapeutic pipeline. Watch the full webinar to learn more and see the live Q&A session.